Savara Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
8analysts covering
FY Revenue (est.)
$2.6Mnext fiscal year
FY EPS (est.)
-$0.58next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| MOLBREEVI FDA PDUFA Target Action Date | 22 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents, and short-term investments Quarterly202.8MTarget: Sufficient capital to fund global commercial launch preparations
Net Loss Quarterly-37.3MTarget: Breakeven projected by fiscal year 2028
Research and Development (R&D) Expenses Quarterly23.4MTarget: Continued investment in MOLBREEVI clinical development and pipeline
Watch Items
- FDA BLA Review for MOLBREEVI (molgramostim inhalation solution) in autoimmune PAPTrigger: PDUFA target action date of November 22, 2026Action: Monitor for FDA approval decision, potential labeling requirements, and commercial launch readiness.
- Executive Leadership TransitionTrigger: Effective date of July 15, 2026Action: Track the transition of Robert Lutz into the combined Chief Financial Officer and Chief Operating Officer role following the resignation of David Lowrance.
- Global Regulatory Submissions (EMA and MHRA)Trigger: Marketing Authorization Applications (MAAs) submitted by end of Q1 2026Action: Monitor validation, review timelines, and potential approval decisions from European and UK regulatory authorities.
Research as of 20 Jun 2026